Larry Anderson, MD, PhD, Discussed Updated Results of the KarMMa Trial at ASCO
June 6th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 2021 ASCO Annual Meeting to talk about updated data from the KarMMa trial of CAR T-cell therapy idecabtagene vicleucel to treat patients with relapsed or refractory multiple myeloma.
Survival Benefit at 7 Years Reported With First-Line Ibrutinib for Chronic Lymphocytic Leukemia
June 5th 2021Median progression-free and overall survival in patients with CLL/SLL receiving ibrutinib in the frontline still not reached at 7-year follow-up, according to data from RESONATE-2 trial reported at the 2021 ASCO Annual Meeting.
Paul M. Barr, MD, Discussed 7-Year Follow-Up Data for Ibrutinib as Frontline Treatment of CLL
June 4th 2021CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about data from RESONATE-2 showing sustained progression-free and overall survival in patients with chronic lymphocytic leukemia being treated with ibrutinib in the frontline setting.
Courtney DiNardo, MD, on Study Methods Evaluating a Doublet, Triplet Regimens in AML
July 8th 2020At the 2020 ASCO Virtual Program, Courtney DiNardo, MD, presented on a study of the combination therapy consisting of ivosenidib plus venetoclax with or without azacytidine patients with IDH1-mutated acute myeloid leukemia.
CARTITUDE-1 Study Results Show Promise for Patients with Relapsed/Refractory Multiple Myeloma
June 13th 2020Jesus G. Berdeja, MD, of the Sarah Cannon Research Institute discussed the CARTITUDE-1 study that examined CAR-T cell therapy to treat patients with relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.
Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
June 5th 2020Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.
KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL
May 31st 2020When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.